Between the uncertainties of science, the fickleness of markets, and really just everything related to the White House, the fate of science and medicine in 2018 seems nigh unpredictable to us. So we reached out to a bunch of people who would know better and asked for their crystal ball readings of what the new year will bring. Here’s what they said.

Get ready for better gene editing

This is a transparent ploy by STAT to get inside info, masquerading as “prediction.” Nevertheless, I’ll be a good sport and give you some options. We may see:

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy